HOME >> BIOLOGY >> NEWS
Targeted therapy knocks out pediatric brain cancer in mice

Scientists have identified what may be the first nontoxic treatment for a subset of medulloblastoma, the most common type of malignant pediatric brain tumor. The finding is encouraging in that such precise, targeted therapies may someday replace traditional treatments that can have overwhelmingly negative side effects for pediatric cancer patients. The research is published in the September issue of Cancer Cell.

"Therapy for pediatric cancers of the central nervous system has not improved significantly in the last three decades," explains study author Dr. Tom Curran from St. Jude Children's Research Hospital in Memphis, Tennessee. "This is partly due to the absence of adequate model systems for testing novel therapies." Dr. Curran and colleagues used a mouse model of medulloblastoma that they had developed to examine whether selective inhibition of the Sonic Hedgehog (Shh) signaling pathway could interfere with the development and progression of the disease. Previous studies have implicated the Shh pathway in human medulloblastoma formation.

Treatment of the mice with a small molecule inhibitor of Shh, HhAntag, resulted in elimination of medulloblastoma. HhAntag administration was associated with the suppression of multiple genes expressed in medulloblastoma as well as reduced cell proliferation and an increase in tumor cell death. Importantly, high doses of HhAntag completely eradicated the tumors, and long-term treatment prolonged medulloblastoma-free survival. No toxic side effects of HhAntag treatment were observed in the mice.

The researchers conclude that the development of compounds that selectively block Shh may be an appropriate direction for designing effective, nontoxic treatments for medulloblastoma. "Ultimately, it is likely that success in treating cancer will require the use of several compounds in concert that target distinct pathways important for tumor cell growth. Our mouse studies with HhAntag offer the hope that suc
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
20-Sep-2004


Page: 1 2

Related biology news :

1. Targeted therapy for lung cancer patients shows promise in extending lives
2. Targeted immunotherapy eradicates cancer in mice
3. Targeted radiation to liver tumors spares tissue, improves quality of life
4. Targeted Genetics presents data on arthritis gene therapy
5. Targeted genetics presents promising data from cystic fibrosis clinical trial
6. Targeted Genetics presents clinical data on E1A cancer gene therapy
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/9/2019)... ... July 08, 2019 , ... On June ... ownership of the innovation behind two Danisco amylase patent applications (EP2859097 and EP2825643). ... based on prior art was without merit and awarded costs to Danisco. ...
(Date:6/20/2019)... Fla. (PRWEB) , ... June 19, 2019 , ... ... recently announced by the Infectious Diseases Society of America Foundation, and the possibly ... on Aging to study infectious agents in AD, are a “welcome affirmation” of ...
(Date:6/14/2019)... ... ... Molecular diagnostics segment is the fastest-growing segment within the global IVD market. The ... are expected to drive the growth are infectious diseases, cancer, and transplant diagnostics. ... The World Molecular Diagnostics Market, 8th Edition . , The discovery of the structure ...
Breaking Biology News(10 mins):
(Date:7/17/2019)... PARK, Md. (PRWEB) , ... July 15, 2019 , ... ... DNA so that a certain trait can be removed, replaced, or edited, but Yiping ... is looking far beyond these traditional applications in his latest publication in Nature Plants. ...
(Date:7/17/2019)... (PRWEB) , ... July 16, ... ... a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene ... Through this collaboration, AveXis, a Novartis company, will have dedicated manufacturing space ...
(Date:7/17/2019)... ... 2019 , ... Quidel is the market leader in point-of-care ... and Siemens Healthineers and Response Biomedical also are among the top companies. The ... (POC) Diagnostics . , Quidel is a market leader in rapid immunoassays and ...
(Date:7/11/2019)... ... ... At the most recent stem cell training course in Las Vegas ... Heroes Program. The Veterans included individuals and families from all over the US, with ... military Veteran, teacher or first responder to receive a regenerative therapy at a training ...
Breaking Biology Technology:
Cached News: